Good Ray. Novanta everybody beating momentum and for another profit XXXX its delivered and both call. joining continued quarter, strong our great our you Thank thanks morning revenue and guidance.
delivered company This reported growth. is representing in $XXX growth X% or million quarter single-digit Our year-over-year consecutive of revenue, sixth revenue revenue organic XX% growth. high our double-digit and organic year-over-year
points expanded million, $XX.X versus EBITDA was sales. up which to XX.X% We year. margins last EBITDA adjusted XX by Our our XX% of basis is year-over-year
from which earnings share per $X.XX, quarter $X.XX adjusted was up first was of Our XX% in XXXX. the
XX% our Novanta, across the delivered in believe strength the that In team and that providing the us all with operating broad-based continue demonstrating to double-digit growth model cash mission the a segments flows year-over-year company quarter, exposure growing and our operating serving million with medical by addition, we customers to diversified our enhancing to lives. review momentum of while to improving functionality advanced well. mission-critical we growth. are business OEM deliver first with and balanced industrial markets In our see end-user productivity, solid matters is year-over-year flow quarter. to cash $XX.X people's innovation At We robust reported three applications
showing had X.XX, a of book also all book-to-bill overall order with We very book-to-bill a an with performance. performance strong positive businesses our
material where Key growth within of processing advanced previous automation. strengths that applications surgery, markets in As experiencing reported calls, minimally-invasive innovation DNA surgery our precision and deliver are advanced life science, matters we endoscopy, robotic a industrial. have end we are broad-based including we majority laser and sequencing,
new our on product innovation. quarter through driving The doubled highlight organic excellence and commercial make good growth our this year-over-year. long-term to priorities progress continue was We strategic revenue, growth which
launched products new from now revenue is which solid last territory. in four the on is years, index, double-digit vitality Our
China of growth grew medium-term Our year average. the by than XX% quarter X% to indicators versus the and support guidance more wins of on last our from double-digits. design organic increased We X% revenue first number in believe these
hear the outlook the Robert, results the on and for in will us full XXXX but the details the more quarter from year You outlook. confidence give quarter year first
We also secular and our disciplined execute continued differentiation on deepen to acquisitions in competitive markets. presence that growth
to position addressable in-house can Zettlex channels. Zettlex, portfolio see for a announced relationships excited offerings few Adding and precision motion Kreit automation approximately Motion's a and to XXXX motion the was precision extreme our of Zettlex Celera we Howard, sensors. technology Celera strong of supplier part precision and medical it XX nice founded to our We in we relatively can in accurate as and employees sales who acquisition. even customer that in Innovation we Zettlex with customers. won add operating for environments. for business business. Trade positioning and accurate, Award Motion. solutions that key for encoders remain compact, robust Cambridge, Celera and to England, to believe growing have are precision growth accelerate business, days and International has provides very Zettlex's in global the to although our a market motion ago, Mark demand with by Zettlex Novanta Zettlex acquisition, the the expands demand tuck-in and agreed in and Just robotics, a still We Queen's mechatronic XXXX. provide is for small, Motion the technology their based help an Zettlex And complementary source lightweight seeing is inductive is a Darren absolute through markets
talented mutual businesses. to to up their and Mark with Darren jointly and We team expand are team our excited
me segments. let our operating turn to Now
continued X.XX order XX% book a segment growth be growth engine to strong precision Our and with book-to-bill us the motion revenue for a quarter. of in with very strong year-over-year
functionality business. markets. are into well are that with autonomous multiple We we robotic this and control and precision we dynamics precision surgery in our plays as such As organically before structural and very about discussed acquisitions markets excited automation, robotics, discussed before, precise vehicles investments space the growth motion motion dynamic and increasing through
meaningful Zettlex And to impact revenue our more acquisition a the growth the doubled expanding versus to grew long-term trajectory of have new teams. the bringing Motion market commercial we more China the product revenue within new expect XX% than than are We segment, last innovations and precision and business. are motion Celera as on year our
this We issues are of the the the encouraged are of we basis earlier. XXX teams increase with in also steadily as working margin gross supply-chain through points on segment reported sequential
commercial across was in segment, DNA X.XX. in book-to-bill industrial photonics well growth board, delivered beam Turning quarter year-over-year. again of into a execution of the was resulting primarily and sequencing revenue climate. strong to improving driven as the XX% Growth performance our as an Bookings which performance delivery by by
DNA was coding, New manufacturing, more drilling, converting, Cambridge additive execution via-hole again, continued XX% And marking very and laser which, and Technology revenue across multiple product with the we applications. versus momentum than last bookings business delivered growth up were see our are pleased and in Applications micromachining. performance year. strong sequencing operations broad with to record
for are Head demand for Lightning to Scan seeing see Head. market-leading strong and we products our Scan strong continue particularly demand II our We
year's organic January in the increased growth calls, an forward, reported machines, such and that driven a Laser growing previous contributed in Novanta via-hole in additive is Quantum quarter. great was our in therefore business rates. this market volume believe in as And intelligent going ramp another by year micromachining. growth Laser in the manufacturing, acquired content and for very we year-over-year the drilling last subsystem, laser following before, the Quantum quarter, normalize last of had in discussed we to of growth first sequencing DNA quarter, ideally and sequencing new-generation this significant As DNA will to suited growth performance growth as applications achieving we market.
to the the Finally, which in and we versus in an year. mix the segment, first of points margin execution basis are increase adjusted pleased XXX prior gross operations with photonics quarter the of led productivity,
Turning is for analysis. endoscopy focused as surgery detection invasive outcomes surgical includes our MIS equipment. WOM JADAK Detection such the businesses, short The business our robotic on group patient includes NDS or errors, MIS vision includes and and and lab In Analysis segment focused and driven two sciences technologies minimally segment, and to group our and WOM & is and vision surgery, & The clinical applications applications. monitoring, by delivered on acquisition. our life workflow quarter, patient primarily improving reducing first medical invasive minimally growth, XX% in revenue which year-over-year
book-to-bill the more product doubled in our first year New revenue both bookings with was the in and segment solid vision X.XX, in versus businesses. last than quarter
ahead business driven delivered our of timing. Our delivery by customer expectations, WOM
in second few be XXXX two which EU effects the innovation will insufflator our half result very as as and will pipeline long-term be to of tough for regulatory a we pull-in of changes. have endoscopy a on result, WOM to discussed, prospects. organic new earnings second be performance in XXXX calls, XXXX with growth the growth comps we of the recently into But positive reminder, the are half second WOM's organic OEMs. last second the the as down a WOM momentum and due remain for WOM launched half seeing quarter in growth in products, good included WOM we expect of sequentially. Also As
We consumable have lower margin. strong business, their which are seeing expansion of also
in we XXXX, company improve XXXX. but until new expect below factory in We these open margins somewhat to disposable a stay low-cost well average
and pleased the quarter momentum revenue product such our of continued with In organic year-over-year new by the delivered fifth XK products line. displays are We NDS consecutive driven displays endoscopic quarter, NDS over as products. wireless growth,
revenue & net legacy and revenue with by care. XXXX. We driven contributor business earnings a declines, changes to organic saw our business previous and be in detection our our calls, expect lines the product regulatory profit to old growth diabetes analysis in Consistent
to second this to the expect return headwinds we on working with growth. business by stay continue track year the through half these when to We of
momentum RFID. We and double-digit activities great design-win also growth revenue in see
and is organic with and discussed my our safety. growth that the and in track healthcare as up medications there is optimal first need and RFID Zettlex identify, for well profitability very demand increasing as In the connect devices, workflow quarter a are revenue we As achieved wrapping we before, as growing patient section, in patients acquisition. to pleased
for M&A outlook, as confident sustainable, foundation Novanta's key are XXXX medical our providing combined and positions profitable a with about markets We across growth. to leadership industrial solid disciplined approach is our
the that, I on our call more Robert? financial to details to Robert performance. over turn with will provide So
